实施例4在外源表达NY-ESO-1的HeLa细胞株和内源表达NY-ESO-1的A375细胞株中,验证NY-ESO-1存在于分离得到的微泡当中
1.将HeLa细胞和A375细胞进行培养至细胞数量达到3×109,培养上清达到300ml后,将上清换成300ml无血清无双抗DMEM,继续培养36小时;
2.收取上清,根据实施例1中的离心方法进行顺序离心,将最后获得的微泡用200ul PBS进行溶解;
3.通过western blot进行目的蛋白的检测:将溶解的微泡进行定量,按照每孔15ug上样于12%的胶当中,跑胶,转膜;室温5%脱脂奶粉封闭1小时;
4.加入针对目标蛋白的特定抗体4℃孵育过夜;
5.PBST洗膜3次,加入相应二抗室温孵育1小时;PBST洗膜3次后加入ECL进行显色曝光。
图5示出了WB检测NY-ESO-1在细胞裂解液和细胞外微泡中的表达。(A)HeLa细胞株中,NY-ESO-1在细胞外微泡中的表达情况,以TSG101,Actin作为参照;(B)HeLa细胞株中,NY-ESO-1在细胞外微泡中的表达情况,以CD63,CD9,Flotillin-1,GM130作为参照;(C)A375中内源NY-ESO-1在细胞外微泡中的表达情况。
以上应用了具体个例对本发明进行阐述,只是用于帮助理解本发明,并不用以限制本发明。对于本发明所属技术领域的技术人员,依据本发明的思想,还可以做出若干简单推演、变形或替换。
参考文献:
1.Accolla RS,Tosi G.Adequate antigen availability:a key issue fornovel approaches to tumor vaccination and tumor immunotherapy.Journal ofneuroimmune pharmacology:the official journal of the Society on NeuroImmunePharmacology,2013;8:28-36.
2.Cerezo-Wallis D,Soengas MS.Understanding Tumor-Antigen Presentationin the New Era of Cancer Immunotherapy.Current pharmaceutical design,2016;22:6234-6250.
3.Coulie PG,Van den Eynde BJ,van der Bruggen P,Boon T.Tumour antigensrecognized by T lymphocytes:at the core of cancer immunotherapy.Naturereviews.Cancer,2014;14:135-146.
4.Simpson AJ,Caballero OL,Jungbluth A,Chen YT,Old LJ.Cancer/testisantigens,gametogenesis and cancer.Nature reviews.Cancer,2005;5:615-625.
5.Chen YT,Scanlan MJ,Sahin U,Tureci O,Gure AO,Tsang S,Williamson B,Stockert E,Pfreundschuh M,Old LJ.A testicular antigen aberrantly expressed inhuman cancers detected by autologous antibody screening.Proceedings of theNational Academy of Sciences of the United States of America,1997;94:1914-1918.
6.Chen YT,Boyer AD,Viars CS,Tsang S,Old LJ,Arden KC.Genomic cloningand localization of CTAG,a gene encoding an autoimmunogenic cancer-testisantigen NY-ESO-1,to human chromosome Xq28.Cytogenetics and cell genetics,1997;79:237-240.
7.Lethe B,Lucas S,Michaux L,De Smet C,Godelaine D,Serrano A,De PlaenE,Boon T.LAGE-1,a new gene with tumor specificity.International journal ofcancer,1998;76:903-908.
8.Alpen B,Gure AO,Scanlan MJ,Old LJ,Chen YT.A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues andevolutionarily conserved.Gene,2002;297:141-149.
9.Fratta E,Coral S,Covre A,Parisi G,Colizzi F,Danielli R,Nicolay HJ,Sigalotti L,Maio M.The biology of cancer testis antigens:putative function,regulation and therapeutic potential.Molecular oncology,2011;5:164-182.
10.Gunda V,Cogdill AP,Bernasconi MJ,Wargo JA,Parangi S.Potential roleof 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy foranaplastic thyroid cancer.Surgery,2013;154:1456-1462;discussion 1462.
11.Gunda V,Frederick DT,Bernasconi MJ,Wargo JA,Parangi S.A potentialrole for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigenexpression.Thyroid:official journal of the American Thyroid Association,2014;24:1241-1250.
12.Gnjatic S,Nishikawa H,Jungbluth AA,Gure AO,Ritter G,Jager E,KnuthA,Chen YT,Old LJ.NY-ESO-1:review of an immunogenic tumor antigen.Advances incancer research,2006;95:1-30.
13.Tureci O,Sahin U,Zwick C,Koslowski M,Seitz G,PfreundschuhM.Identification of a meiosis-specific protein as a member of the class ofcancer/testis antigens.Proceedings of the National Academy of Sciences of theUnited States of America,1998;95:5211-5216.
14.Ono T,Kurashige T,Harada N,Noguchi Y,Saika T,Niikawa N,Aoe M,Nakamura S,Higashi T,Hiraki A,Wada H,Kumon H,Old LJ,Nakayama E.Identificationof proacrosin binding protein sp32 precursor as a human cancer/testisantigen.Proceedings of the National Academy of Sciences of the United Statesof America,2001;98:3282-3287.
15.Cilensek ZM,Yehiely F,Kular RK,Deiss LP.A member of the GAGEfamily of tumor antigens is an anti-apoptotic gene that confers resistance toFas/CD95/AP0-1,interferon-gamma,taxol and gamma-irradiation.Cancer biology&therapy,2002;1:380-387.
16.Kisseleva-Romanova E,Lopreiato R,Baudin-Baillieu A,Rousselle JC,Ilan L,Hofmann K,Namane A,Mann C,Libri D.Yeast homolog of a cancer-testisantigen defines a new transcription complex.The EMBO journal,2006;25:3576-3585.
17.Cho HJ,Caballero OL,Gnjatic S,Andrade VC,Colleoni GW,Vettore AL,Outtz HH,Fortunato S,Altorki N,Ferrera CA,Chua R,Jungbluth AA,Chen YT,Old LJ,Simpson AJ.Physical interaction of two cancer-testis antigens,MAGE-C1(CT7)andNY-ESO-1(CT6).Cancer immunity,2006;6:12.
18.Cronwright G,Le Blanc K,Gotherstrom C,Darcy P,Ehnman M,BrodinB.Cancer/testis antigen expression in human mesenchymal stem cells:down-regulation of SSX impairs cell migration and matrix metalloproteinase 2expression.Cancer research,2005;65:2207-2215.
19.Hayes SJ,Hng KN,Clark P,Thistlethwaite F,Hawkins RE,AngY.Immunohistochemical assessment of NY-ESO-1 expression in esophagealadenocarcinoma resection specimens.World journal of gastroenterology,2014;20:4011-4016.
20.Komatsu N,Jackson HM,Chan KF,Oveissi S,Cebon J,Itoh K,Chen W.Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients'sera using short overlapping peptides and full-length recombinantprotein.Molecular immunology,2013;54:465-471.
21.Esfandiary A,Ghafouri-Fard S.New York esophageal squamous cellcarcinoma-1 and cancer immunotherapy.Immunotherapy,2015;7:411-439.
22.Luetkens T,Kobold S,Cao Y,Ristic M,Schilling G,Tams S,Bartels BM,Templin J,Bartels K,Hildebrandt Y,Yousef S,Marx A,Haag F,Bokemeyer C,KrogerN,Atanackovic D.Functional autoantibodies against SSX-2 and NY-ESO-1 inmultiple myeloma patients after allogeneic stem cell transplantation.Cancerimmunology,immunotherapy:CII,2014;63:1151-1162.
23.Jager E,Gnjatic S,Nagata Y,Stockert E,Jager D,Karbach J,Neumann A,Rieckenberg J,Chen YT,Ritter G,Hoffman E,Arand M,Old LJ,Knuth A.Induction ofprimary NY-ESO-1 immunity:CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers.Proceedings of the National Academyof Sciences of the United States of America,2000;97:12198-12203.
24.Gnjatic S,Jager E,Chen W,Altorki NK,Matsuo M,Lee SY,Chen Q,NagataY,Atanackovic D,Chen YT,Ritter G,Cebon J,Knuth A,Old LJ.CD8(+)T cellresponses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptideimmunization of cancer patients.Proceedings of the National Academy ofSciences of the United States of America,2002;99:11813-11818.
25.Nicholaou T,Ebert L,Davis ID,Robson N,Klein O,Maraskovsky E,ChenW,Cebon J.Directions in the immune targeting of cancer:lessons learned fromthe cancer-testis AgNY-ESO-1.Immunology and cell biology,2006;84:303-317.
26.Groeper C,Gambazzi F,Zajac P,Bubendorf L,Adamina M,Rosenthal R,Zerkowski HR,Heberer M,Spagnoli GC.Cancer/testis antigen expression andspecific cytotoxic Tlymphocyte responses in non small cell lungcancer.International journal of cancer,2007;120:337-343.
27.Riener MO,Wild PJ,Soll C,Knuth A,Jin B,Jungbluth A,Hellerbrand C,Clavien PA,Moch H,Jochum W.Frequent expression of the novel cancer testisantigen MAGE-C2/CT-10 in hepatocellular carcinoma.International journal ofcancer,2009;124:352-357.
28.Gupta A,Nuber N,Esslinger C,Wittenbrink M,Treder M,Landshammer A,Noguchi T,Kelly M,Gnjatic S,Ritter E,von Boehmer L,Nishikawa H,Shiku H,Old L,Ritter G,Knuth A,van den Broek M.A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.Cancer immunity,2013;13:3.
29.Jager E,Nagata Y,Gnjatic S,Wada H,Stockert E,Karbach J,Dunbar PR,Lee SY,Jungbluth A,Jager D,Arand M,Ritter G,Cerundolo V,Dupont B,Chen YT,OldLJ,Knuth A.Monitoring CD8 T cell responses to NY-ESO-1:correlation of humoraland cellular immune responses.Proceedings of the National Academy of Sciencesof the United States of America,2000;97:4760-4765.
30.Johannsen A,Genolet R,Legler DF,Luther SA,Luescher IF.Definitionof key variables for the induction of optimal NY-ESO-1-specific T cells inHLA transgene mice.Journal of immunology,2010;185:3445-3455.
31.Rapoport AP,Stadtmauer EA,Binder-Scholl GK,Goloubeva O,Vogl DT,Lacey SF,Badros AZ,Garfall A,Weiss B,Finklestein J,Kulikovskaya I,Sinha SK,Kronsberg S,Gupta M,Bond S,Melchiori L,Brewer JE,Bennett AD,Gerry AB,PumphreyNJ,Williams D,Tayton-Martin HK,Ribeiro L,Holdich T,Yanovich S,Hardy N,YaredJ,Kerr N,Philip S,Westphal S,Siegel DL,Levine BL,Jakobsen BK,Kalos M,JuneCH.NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Nature medicine,2015;21:914-921.
32.Rosenberg SA,Yang JC,Sherry RM,Kammula US,Hughes MS,Phan GQ,CitrinDE,Restifo NP,Robbins PF,Wunderlich JR,Morton KE,Laurencot CM,Steinberg SM,White DE,Dudley ME.Durable complete responses in heavily pretreated patientswith metastatic melanoma using T-cell transfer immunotherapy.Clinical cancerresearch:an official journal of the American Association for Cancer Research,2011;17:4550-4557.
33.Robbins PF,Morgan RA,Feldman SA,Yang JC,Sherry RM,Dudley ME,Wunderlich JR,Nahvi AV,Helman LJ,Mackall CL,Kammula US,Hughes MS,Restifo NP,Raffeld M,Lee CC,Levy CL,Li YF,El-Gamil M,Schwarz SL,Laurencot C,RosenbergSA.Tumor regression in patients with metastatic synovial cell sarcoma andmelanoma using genetically engineered lymphocytes reactive with NY-ESO-1.Journal of clinical oncology:official journal of the American Society ofClinical Oncology,2011;29:917-924.